[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100538164":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":19,"centralContacts":23,"locations":29,"responsibleParty":154,"collaborators":10,"id":156,"slug":157,"hasResults":158,"nctId":159,"briefTitle":160,"officialTitle":161,"acronym":10,"eligibilityCriteria":162,"healthyVolunteers":158,"sex":163,"minAge":164,"maxAge":165,"enrollmentInfo":166,"targetDuration":10,"studyType":169,"phases":10,"briefSummary":170,"conditions":171,"keywords":173,"overallStatus":32,"whyStopped":10,"lastUpdateSubmitDate":179,"lastUpdatePostDateStruct":180,"startDateStruct":183,"completionDateStruct":185,"leadSponsor":187,"locationsCount":188},{"fullName":5,"class":6},"Novartis","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"eltrombopag",null,"ATG treatment naïve pediatric patients with AA in routine clinical practice",[13],"Other: eltrombopag",[15],{"type":16,"name":9,"description":17,"armGroupLabels":18,"otherNames":10},"OTHER","This is an observational study. There is no treatment allocation. After confirming that patients are fulfilling the eligibility criteria, patients will be registered in this survey.",[9],[20],{"name":21,"affiliation":21,"role":22},"Novartis Pharmaceuticals","STUDY_DIRECTOR",[24,28],{"name":21,"role":25,"phone":26,"phoneExt":10,"email":27},"CONTACT","+81337978748","novartis.email@novartis.com",{"name":21,"role":25,"phone":10,"phoneExt":10,"email":10},[30,44,49,57,65,74,82,91,95,104,111,119,127,131,135,143,146],{"facility":31,"status":32,"city":33,"state":34,"zip":35,"country":36,"countryCode":37,"cosmosGeoPoint":38,"geoPoint":43,"contacts":10},"Novartis Investigative Site","RECRUITING","Nagoya","Aichi-ken","453-8511","Japan","JP",{"type":39,"coordinates":40},"Point",[41,42],136.90641,35.18147,{"lat":42,"lon":41},{"facility":31,"status":32,"city":33,"state":34,"zip":45,"country":36,"countryCode":37,"cosmosGeoPoint":46,"geoPoint":48,"contacts":10},"4668560",{"type":39,"coordinates":47},[41,42],{"lat":42,"lon":41},{"facility":31,"status":32,"city":50,"state":34,"zip":51,"country":36,"countryCode":37,"cosmosGeoPoint":52,"geoPoint":56,"contacts":10},"Toyoake","4701192",{"type":39,"coordinates":53},[54,55],136.99931,35.038,{"lat":55,"lon":54},{"facility":31,"status":32,"city":58,"state":58,"zip":59,"country":36,"countryCode":37,"cosmosGeoPoint":60,"geoPoint":64,"contacts":10},"Chiba","260 8677",{"type":39,"coordinates":61},[62,63],140.11667,35.6,{"lat":63,"lon":62},{"facility":31,"status":32,"city":66,"state":67,"zip":68,"country":36,"countryCode":37,"cosmosGeoPoint":69,"geoPoint":73,"contacts":10},"Amagasaki","Hyōgo","660 8550",{"type":39,"coordinates":70},[71,72],135.41667,34.71667,{"lat":72,"lon":71},{"facility":31,"status":32,"city":75,"state":67,"zip":76,"country":36,"countryCode":37,"cosmosGeoPoint":77,"geoPoint":81,"contacts":10},"Kobe","6500047",{"type":39,"coordinates":78},[79,80],135.183,34.6913,{"lat":80,"lon":79},{"facility":31,"status":32,"city":83,"state":84,"zip":85,"country":36,"countryCode":37,"cosmosGeoPoint":86,"geoPoint":90,"contacts":10},"Matsumoto","Nagano","3908621",{"type":39,"coordinates":87},[88,89],137.96667,36.23333,{"lat":89,"lon":88},{"facility":31,"status":32,"city":92,"state":93,"zip":94,"country":36,"countryCode":37,"cosmosGeoPoint":10,"geoPoint":10,"contacts":10},"Shimajiri-Gun","Okinawa","901-1303",{"facility":31,"status":32,"city":96,"state":97,"zip":98,"country":36,"countryCode":37,"cosmosGeoPoint":99,"geoPoint":103,"contacts":10},"Izumi","Osaka","5941101",{"type":39,"coordinates":100},[101,102],135.43333,34.48333,{"lat":102,"lon":101},{"facility":31,"status":32,"city":97,"state":97,"zip":105,"country":36,"countryCode":37,"cosmosGeoPoint":106,"geoPoint":110,"contacts":10},"5340021",{"type":39,"coordinates":107},[108,109],135.50107,34.69379,{"lat":109,"lon":108},{"facility":31,"status":32,"city":112,"state":97,"zip":113,"country":36,"countryCode":37,"cosmosGeoPoint":114,"geoPoint":118,"contacts":10},"Sakai","590-0197",{"type":39,"coordinates":115},[116,117],135.46653,34.58216,{"lat":117,"lon":116},{"facility":31,"status":32,"city":120,"state":120,"zip":121,"country":36,"countryCode":37,"cosmosGeoPoint":122,"geoPoint":126,"contacts":10},"Saitama","3308777",{"type":39,"coordinates":123},[124,125],139.65657,35.90807,{"lat":125,"lon":124},{"facility":31,"status":32,"city":128,"state":129,"zip":130,"country":36,"countryCode":37,"cosmosGeoPoint":10,"geoPoint":10,"contacts":10},"Ohtsu","Shiga","5202192",{"facility":31,"status":32,"city":132,"state":133,"zip":134,"country":36,"countryCode":37,"cosmosGeoPoint":10,"geoPoint":10,"contacts":10},"Chuo Ku","Tokyo","1048560",{"facility":31,"status":32,"city":136,"state":133,"zip":137,"country":36,"countryCode":37,"cosmosGeoPoint":138,"geoPoint":142,"contacts":10},"Ōta-ku","143 8541",{"type":39,"coordinates":139},[140,141],139.71605,35.56126,{"lat":141,"lon":140},{"facility":31,"status":32,"city":144,"state":133,"zip":145,"country":36,"countryCode":37,"cosmosGeoPoint":10,"geoPoint":10,"contacts":10},"Setagaya-ku","1578535",{"facility":31,"status":32,"city":147,"state":147,"zip":148,"country":36,"countryCode":37,"cosmosGeoPoint":149,"geoPoint":153,"contacts":10},"Wakayama","641-8510",{"type":39,"coordinates":150},[151,152],135.16667,34.23333,{"lat":152,"lon":151},{"type":155,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100538164","revolade-tablets-specified-drug-use-survey-100538164",false,"NCT06287268","Revolade Tablets Specified Drug-use Survey","Revolade Tablets Specified Drug-use Survey (Pediatric Aplastic Anemia Naive to Treatment With Anti-thymocyte Immunoglobulin, CETB115G1401)","Inclusion Criteria:\n\n* Patients whose legally acceptable representative has given written consent for cooperation in this survey prior to enrollment in this survey\n* Patients aged ≥ 6 years and \\\u003C 18 years at the start of treatment with eltrombopag\n* Pediatric patients with AA who receive eltrombopag for the first time in combination with ATG after the approval of additional dosage and administration for \"ATG-naïve pediatric patients with AA\"\n\nExclusion Criteria:\n\n* Patients who have received ATG without concomitant use of eltrombopag\n* Patients with congenital AA\n* Patients with suspected or confirmed diagnosis of myelodysplastic syndrome (MDS) at the start of treatment with eltrombopag\n* Patients who have received any drug products containing the same ingredient as eltrombopag (including investigational products)","ALL","6 Years","17 Years",{"count":167,"type":168},10,"ESTIMATED","OBSERVATIONAL","This is a multicenter, single-arm, non-interventional study (NIS) to confirm the safety and efficacy of eltrombopag in Anti-Thymocyte Globulin (ATG) treatment naive pediatric patients with aplastic anemia (AA).",[172],"Aplastic Anemia",[174,175,176,177,9,178],"NIS","Pediatric Aplastic Anemia","AA","Revolade Tablets","Drug-use Survey","2026-02-18",{"date":181,"type":182},"2026-02-19","ACTUAL",{"date":184,"type":182},"2024-07-17",{"date":186,"type":168},"2028-10-31",{"name":21,"class":6},17]